您搜索了: addendum (希腊语 - 英语)

ΠΡΟΣΘΗΚΗ (addendum)1 ,(3)
addendum

Παράρτημα: ces 1002/98 addendum
addendum: ces 1002/98 addendum

2) – addendum on paediatric oncology.
note for guidance on clinical investigation of medical products in the treatment of obsessive-compulsive disorder

addendum – εισηγήτρια : η κα cassina)
addendum – rapporteur: mrs cassina)

Προσθήκη (addendum) στα συμπεράσματα της προεδρίας
violence and terror have no place in the search for a just and lasting peace in the middle east.

addendum to ich e2c – clinical safety data management:
addendum to ich e2c – clinical safety data management:

Σειρά : ΓΝΩΜΟΔΟΤΗΣΕΙΣ ΚΑΙ ΕΚΘΕΣΕΙΣ ΕτΠ cdr(2000) 123 addendum
series : cor opinions and reports cdr(2000) 123 addendum

concept paper on the development of an addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure
concept paper on the development of an addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure

Προσθήκη (addendum) στα συμπεράσματα της προεδρίας εναρμόνιση των κειμένων, προκειμένου να υπογρα­φεί η Συνθήκη πριν από τα τέλη του 2004.
addendum to the presidency conclusions vigorously the course set out in the roadmap and calls on both sides to fulfil their obligations under the roadmap.

* "addendum to m68000 user manual (rev 0)"; motorola (freescale); 26 pages; 1997.
* "addendum to m68000 user manual (rev 0)"; motorola (freescale); 26 pages; 1997.

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: